GlassScriptPhysician profile
Carrie Casden
NPI 1386937746
$5,370.24
in general payments reported to CMS, 2019-2025
38 companies · $870 in 2025
The $870 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $864 · 2020: $412 · 2021: $408 · 2022: $567 · 2023: $1,252 · 2024: $997 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,119.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $718.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $574.34 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Mannkind Corporation | $564.22 | 2019-2023 | Afrezza |
| Dexcom, INC. | $416.03 | 2019-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $346.84 | 2019-2023 | Farxiga |
| Amgen INC. | $339.60 | 2019-2025 | Tepezza, Evenity, Prolia |
| Abbott Laboratories | $301.75 | 2019-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $237.82 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.47 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $149.44 | 2021-2023 | Nexletol |
| Sanofi-Aventis U.S. LLC | $146.43 | 2019-2025 | |
| Corcept Therapeutics | $144.66 | 2023-2025 | Korlym |
| Tandem Diabetes Care, INC. | $139.34 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novartis Pharmaceuticals Corporation | $134.72 | 2023-2025 | |
| Amarin Pharma, INC. | $109.00 | 2019-2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Casden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.